AKT1 and metabolic dysfunction-associated steatotic liver disease: In addition, it was found that Cynarine was mainly designed to treat NAFLD with the PI3K-Akt signaling pathway and MAPK signaling pathway, and it was finally concluded that Cynarine could significantly reduce the fat deposition capacity of NAFLD model cells.